1-2 of 2
William M Garrett, MBA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro Vannucchi
Journal: Blood
Blood (2009) 114 (22): 311.
https://doi.org/10.1182/blood.V114.22.311.311
Published: 2009
Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 631.
https://doi.org/10.1182/blood.V114.22.631.631
Published: 2009